ASTRO releases breast RT guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation.

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation. The guidelines state that hypofractionated whole-breast irradiation is effective for patients with early-stage breast cancer who meet certain criteria, including age 50 years and older and stage T1-2 N0 disease. Also, eligible patients will not have received chemotherapy. In addition, the radiation oncologist must be able to provide a relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam.

For patients who do not meet these criteria, there was not enough evidence to reach a consensus for or against the use of hypofractionated whole-breast irradiation (Int J Radiat Oncol Biol Phys online, July 15, 2010).

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content